Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (PLANET II)

• ClinicalTrials.gov Identifier: NCT00296400
• Recruitment Status: Completed
• First Posted: February 27, 2006
• Results First Posted: December 30, 2010
• Last Update Posted: June 16, 2011
• Sponsor: AstraZeneca
• Information provided by: AstraZeneca

• Study Type: Interventional
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Hyperlipidemia
• Interventions: Drug: Rosuvastatin; Drug: Atorvastatin
• Enrollment: 237

Participant Flow

Recruitment Details	797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.
Pre-assignment Details	237 patients [pts] completed the 8-week lead-in period and were randomized. The most common reasons for discontinuation during the lead in period included incorrect enrollment (466 pts), development of study-specific discontinuation criteria (41 pts), and voluntary discontinuation (29 pts). 189 patients completed the study.

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description	[Not Specified]	[Not Specified]	[Not Specified]
Period Title: Overall Study
Started	70	87	80
Completed	53	69	67
Not Completed	17	18	13
Reason Not Completed
Adverse Event	7	7	7
Withdrawal by Subject	5	6	2
Incorrect enrollment	2	0	0
Protocol Violation	1	1	1
Lost to Follow-up	1	1	2
Study specific discontinuation criteria	0	0	1
Visit 10 was performed earlier	0	1	0
Pregnancy	1	2	0

Baseline Characteristics

Arm/Group Title		Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg	Total
Arm/Group Description		[Not Specified]	[Not Specified]	[Not Specified]	Total of all reporting groups
Overall Number of Baseline Participants		70	87	80	237
Baseline Analysis Population Description		[Not Specified]
Age, Customized; Measure Type: Number; Unit of measure: Participants	Number Analyzed	70 participants	87 participants	80 participants	237 participants
18 to 49 years		34	44	42	120
50 to 64 years		31	31	30	92
>=65 years		5	12	8	25
Sex: Female, Male; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	70 participants	87 participants	80 participants	237 participants
	Female	28 40.0%	35 40.2%	31 38.8%	94 39.7%
	Male	42 60.0%	52 59.8%	49 61.3%	143 60.3%
Estimated glomerular filtration rate [eGFR]; Mean (Standard Deviation); Unit of measure: mL/min
	Number Analyzed	70 participants	87 participants	80 participants	237 participants
		78.315 (28.0653)	76.774 (30.3878)	71.464 (30.0156)	75.419 (29.6012)
Urine albumin/creatinine ratio; Mean (Standard Deviation); Unit of measure: Mg/g
	Number Analyzed	70 participants	87 participants	80 participants	237 participants
		1023.165 (720.0251)	1167.368 (865.4584)	1069.103 (720.8011)	1091.263 (775.1889)
Urine protein/creatinine ratio; Mean (Standard Deviation); Unit of measure: Mg/g
	Number Analyzed	70 participants	87 participants	80 participants	237 participants
		1301.163 (832.7398)	1487.131 (1068.0642)	1439.720 (991.2295)	1416.023 (975.7636)

Outcome Measures

1. Primary Outcome

Title	Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
Description	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time Frame	Assessed at baseline and Week 52 (LOCF)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	65	80	75
Geometric Mean (95% Confidence Interval); Unit of Measure: ratio
	0.938; (0.725 to 1.212)	1.082; (0.927 to 1.262)	0.759; (0.636 to 0.905)

2. Secondary Outcome

Title	Urinary Protein/Creatinine Ratio at Week 26.
Description	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time Frame	Assessed at baseline and Week 26

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	59	76	70
Geometric Mean (95% Confidence Interval); Unit of Measure: ratio
	0.932; (0.721 to 1.203)	1.057; (0.898 to 1.244)	0.762; (0.631 to 0.921)

3. Secondary Outcome

Title	Urinary Albumin/Creatinine Ratio at Week 26
Description	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time Frame	Assessed at baseline and Week 26

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	60	76	72
Geometric Mean (95% Confidence Interval); Unit of Measure: ratio
	0.850; (0.631 to 1.143)	0.946; (0.789 to 1.135)	0.731; (0.601 to 0.889)

4. Secondary Outcome

Title	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Description	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 [LOCF] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time Frame	Assessed at baseline and Week 52 [LOCF]

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	65	80	75
Geometric Mean (95% Confidence Interval); Unit of Measure: ratio
	0.879; (0.652 to 1.185)	0.967; (0.814 to 1.148)	0.719; (0.587 to 0.882)

5. Secondary Outcome

Title	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Description	The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
Time Frame	Assessed at baseline and Week 26

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	60	77	72
Mean (Standard Deviation); Unit of Measure: mL/min
	1.39 (15.431)	-3.41 (13.228)	-1.61 (9.494)

6. Secondary Outcome

Title	Change From Baseline in eGFR at Week 52 [LOCF]
Description	The change from baseline in eGFR at Week 52 [LOCF] is the Week 52 value or last observation carried forward minus baseline value.
Time Frame	Assessed at baseline and Week 52 [LOCF]

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description:	[Not Specified]	[Not Specified]	[Not Specified]
Overall Number of Participants Analyzed	65	80	75
Mean (Standard Deviation); Unit of Measure: mL/min
	-2.71 (13.083)	-3.30 (12.325)	-1.74 (13.964)

7. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	70	205
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.17601	0.21701	0.19643

8. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	64	185
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20462	0.03480	0.16077

9. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.14302	0.24393	0.17632

10. Secondary Outcome

Title	Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.16868	-0.09428	0.10679

11. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.18055	0.24987	0.22094

12. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20346	0.18041	0.20818

13. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.16206	0.20032	0.17628

14. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20386	-0.04698	0.14495

15. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	70	205
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.15348	-0.06049	0.10089

16. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	64	185
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20659	0.23989	0.21728

17. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.04652	0.06344	0.04149

18. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.03957	-0.17644	-0.01549

19. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.06383	0.12687	0.07462

20. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.05881	-0.20262	-0.01340

21. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	135	69	204
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.06794	0.05410	0.05465

22. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	62	183
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.07188	-0.16669	0.00955

23. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	67	198
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.12595	0.05628	0.13754

24. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	62	178
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.19626	0.09835	0.18349

25. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	67	198
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.18504	0.17259	0.19146

26. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	62	178
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.18473	-0.02690	0.12496

27. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	67	198
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.10698	0.13814	0.11414

28. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Description	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	62	178
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.05859	-0.12938	-0.00540

29. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	72	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.18188	0.17503	0.18566

30. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	65	186
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.23734	0.01311	0.17958

31. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.14783	0.21561	0.16899

32. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20285	-0.13565	0.12568

33. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.23547	0.25043	0.25208

34. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.17479	0.18677	0.18203

35. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.16080	0.17150	0.16578

36. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.24107	-0.08640	0.16525

37. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	72	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.11526	-0.06890	0.07248

38. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	65	186
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.21730	0.21151	0.21477

39. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.02506	0.02201	0.01860

40. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.08954	-0.20870	0.01926

41. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.05037	0.09779	0.05936

42. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.10365	-0.24717	0.01386

43. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	136	71	207
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.04955	0.02740	0.03798

44. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.11997	-0.21073	0.03955

45. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	68	199
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.16499	0.02609	0.15049

46. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.20021	0.12953	0.18870

47. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	68	199
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.18720	0.16167	0.18717

48. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.21082	-0.04379	0.14085

49. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	131	68	199
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.10258	0.13505	0.11103

50. Secondary Outcome

Title	Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Description	Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.08108	-0.16753	0.00479

51. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	72	209
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.06641	-0.07964	0.02900

52. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	65	186
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.15721	0.16110	-0.05794

53. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.02679	-0.07603	-0.00171

54. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.15731	0.15368	-0.06310

55. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.01684	0.01755	0.01758

56. Secondary Outcome

Title	Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.14080	0.02750	0.09472

57. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.06029	-0.08151	0.02283

58. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.19532	0.14967	-0.09001

59. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	72	209
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.04160	0.00531	0.03430

60. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	65	186
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.12643	0.00486	-0.08301

61. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.08194	-0.06576	0.04477

62. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.23597	0.19933	-0.10205

63. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.04858	-0.05535	0.02023

64. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.20805	0.18299	-0.07681

65. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	137	71	208
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.08263	-0.06860	0.04337

66. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	121	63	184
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.23887	0.17170	-0.10817

67. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	132	68	200
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.13029	0.17554	0.14191

68. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.11047	0.07751	0.08580

69. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	132	68	200
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.06098	-0.03181	0.03861

70. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.11217	0.11006	-0.03932

71. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 26 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	132	68	200
Measure Type: Number; Unit of Measure: Correlation coefficient
	0.02907	-0.09476	-0.00160

72. Secondary Outcome

Title	Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Description	Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time Frame	Baseline and 52 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Rosuvastatin	Atorvastatin	All Treatments
Arm/Group Description:	Rosuvastatin Treatments pooled	Atorvastatin Treatment	All Treatments pooled
Overall Number of Participants Analyzed	116	63	179
Measure Type: Number; Unit of Measure: Correlation coefficient
	-0.15415	0.10486	-0.06121

Adverse Events

Time Frame	[Not Specified]
Adverse Event Reporting Description	[Not Specified]
Arm/Group Title	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
Arm/Group Description	[Not Specified]	[Not Specified]	[Not Specified]
All-Cause Mortality
	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected / at Risk (%)	Affected / at Risk (%)	Affected / at Risk (%)
Total	--/--	--/--	--/--
Serious Adverse Events
	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected / at Risk (%)	Affected / at Risk (%)	Affected / at Risk (%)
Total	10/69 (14.49%)	6/87 (6.90%)	5/80 (6.25%)
Cardiac disorders
Cardiac Failure † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Cardiac Failure Congestive † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Gastrointestinal disorders
Enterocolitis † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Dyspepsia † 1	0/69 (0.00%)	0/87 (0.00%)	1/80 (1.25%)
Gastritis † 1	0/69 (0.00%)	0/87 (0.00%)	1/80 (1.25%)
Gastrointestinal Haemorrhage † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
General disorders
Oedema Peripheral † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
Infections and infestations
Bronchitis † 1	2/69 (2.90%)	0/87 (0.00%)	1/80 (1.25%)
Injury, poisoning and procedural complications
Lumbar Vertebral Fracture † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Humerus Fracture † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
Meniscus Lesion † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
Metabolism and nutrition disorders
Fluid Retention † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Musculoskeletal and connective tissue disorders
Intervertebral Disc Protrusion † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Musculoskeletal Chest Pain † 1	0/69 (0.00%)	0/87 (0.00%)	1/80 (1.25%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional Cell Carcinoma † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Breast Cancer † 1	0/69 (0.00%)	0/87 (0.00%)	1/80 (1.25%)
Nervous system disorders
Hypertensive Encephalopathy † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Intracranial Aneurysm † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
Renal and urinary disorders
Renal Colic † 1	1/69 (1.45%)	0/87 (0.00%)	0/80 (0.00%)
Nephrotic Syndrome † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
Respiratory, thoracic and mediastinal disorders
Epistaxis † 1	0/69 (0.00%)	0/87 (0.00%)	1/80 (1.25%)
Vascular disorders
Hypertension † 1	0/69 (0.00%)	1/87 (1.15%)	0/80 (0.00%)
† Indicates events were collected by systematic assessment; 1 Term from vocabulary, MedDRA 12.0
Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events	5%
	Rosuvastatin 10 mg	Rosuvastatin 40 mg	Atorvastatin 80 mg
	Affected / at Risk (%)	Affected / at Risk (%)	Affected / at Risk (%)
Total	15/69 (21.74%)	16/87 (18.39%)	17/80 (21.25%)
Gastrointestinal disorders
Nausea † 1	2/69 (2.90%)	6/87 (6.90%)	0/80 (0.00%)
Infections and infestations
Nasopharyngitis † 1	3/69 (4.35%)	6/87 (6.90%)	7/80 (8.75%)
Bronchitis † 1	4/69 (5.80%)	0/87 (0.00%)	0/80 (0.00%)
Blood Creatine Phosphokinase Increased † 1	3/69 (4.35%)	3/87 (3.45%)	4/80 (5.00%)
Musculoskeletal and connective tissue disorders
Myalgia † 1	4/69 (5.80%)	3/87 (3.45%)	5/80 (6.25%)
Nervous system disorders
Dizziness † 1	0/69 (0.00%)	1/87 (1.15%)	4/80 (5.00%)
† Indicates events were collected by systematic assessment; 1 Term from vocabulary, MedDRA 12.0

Limitations and Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

• Name/Title: Gerard Lynch
• Organization: AstraZeneca
• EMail: aztrial_results_posting@astrazeneca.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.

• Responsible Party: MSD, AstraZeneca
• ClinicalTrials.gov Identifier: NCT00296400
• Other Study ID Numbers: D3569C00011; PLANET II
• First Submitted: February 23, 2006
• First Posted: February 27, 2006
• Results First Submitted: March 22, 2010
• Results First Posted: December 30, 2010
• Last Update Posted: June 16, 2011